VIDEO: Mepolizumab for EoE does not yield ‘prominent symptom improvement’ after 6 months

CHICAGO — In this Healio video, Evan S. Dellon, MD, MPH, explains that while mepolizumab outperformed placebo at 3 months, there were no additional symptom or endoscopic improvements at 6 months in patients with eosinophilic esophagitis.“This study came about because of the need for additional treatments for EoE,” Dellon, professor of medicine and director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, said. “Second, the mechanism of this medication, which is blocking [interleukin 5], is one of the keyRead More

Generated by Feedzy